42 results
6-K
EX-99.1
TAK
Takeda Pharmaceutical Company Limited
10 Jul 24
Current report (foreign)
6:04am
(formerly known as the Carbon Disclosure Project), the Company discloses its strategies, initiatives, and impacts related to climate change annually. 2024
6-K
EX-99.1
TAK
Takeda Pharmaceutical Company Limited
1 Jul 24
Current report (foreign)
6:33am
position Takeda to achieve our ambitious net-zero targets. We have transitioned away from carbon neutrality as a climate goal to focus our resources … the Corporate Net-Zero Standard), we will continue to invest in nature-based carbon removal projects, prioritizing solutions that benefit human health. Scope 1
6-K
EX-99.1
TAK
Takeda Pharmaceutical Company Limited
29 May 24
Current report (foreign)
6:29am
chain. While Takeda has endeavored to be carbon neutral since 2020 (reflecting FY2019 greenhouse gas emissions), beginning in FY2024 we will fully … dedicate our resources to decarbonizing our operations and value chain to support our net-zero ambition, and will no longer have carbon neutrality
6-K
EX-99.1
TAK
Takeda Pharmaceutical Company Limited
29 May 24
Current report (foreign)
6:24am
maintained carbon neutrality through FY2022, in FY2024 we have transitioned away from carbon neutrality as a climate goal and are focusing resources … on initiatives that advance our net-zero roadmap while continuing to invest in nature-based carbon removal projects in projects beyond our value chain. We
6-K
x8tv2k2p753
9 May 24
Current report (foreign)
6:01am
6-K
g7eua
1 Feb 24
Current report (foreign)
6:18am
6-K
EX-99.1
lnmrq
1 Feb 24
Current report (foreign)
6:06am
6-K
EX-99.1
bj6heo2q3uqg
14 Dec 23
Current report (foreign)
6:01am
6-K
EX-99.1
9vt0bdpa
30 Nov 23
Current report (foreign)
6:01am
6-K
EX-99.1
n9mq2izbiutked
30 Oct 23
Current report (foreign)
6:02am
6-K
EX-99.1
mmfnvde4
26 Oct 23
Current report (foreign)
6:20am
6-K
EX-99.1
hauy f92kb9mz
27 Jul 23
Current report (foreign)
6:05am
6-K
EX-99.1
ec4 s3q2m
12 Jul 23
Current report (foreign)
6:07am
6-K
EX-99.1
x3wemqxyjpp1kml
6 Jul 23
Current report (foreign)
6:18am
6-K
EX-99.1
98d32c6fw34084a3zn
11 May 23
Current report (foreign)
6:07am
6-K
w9wb0mkz9jh7zvriodux
13 Dec 22
Takeda to Acquire Late-Stage, Potential Best-in-Class, Oral Allosteric TYK2 Inhibitor NDI-034858 From Nimbus Therapeutics
7:00am
6-K
EX-99.1
ektb3egnn5q6 7dq
30 Nov 22
Current report (foreign)
6:28am
6-K
EX-99.1
045x2s
27 Oct 22
Current report (foreign)
6:01am